PTE - PolarityTE, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.8300
+0.2400 (+9.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.5900
Open2.9000
Bid2.6800 x 2900
Ask2.8800 x 900
Day's Range2.7100 - 2.9500
52 Week Range2.1000 - 18.1700
Volume108,106
Avg. Volume266,130
Market Cap79M
Beta (3Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-01-12
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    PolarityTE Announces Equity Purchase Agreement for up to $25 Million with Keystone Capital Partners

    PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has entered into a $25.0 million equity purchase agreement (the "Agreement") with Keystone Capital Partners, LLC ("Keystone"), a New York-based institutional investor.

  • Business Wire

    PolarityTE to Attend Evercore ISI 2nd Annual HealthCONx Conference and Piper Jaffray 31st Annual Healthcare Conference

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will attend the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2019 in Boston and the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 in New York, NY.

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PolarityTE, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • Business Wire

    PolarityTE Reports Third Calendar Quarter 2019 Results

    PolarityTE, Inc. , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2019.

  • Business Wire

    PolarityTE Adopts Short-Term Shareholder Rights Plan

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that its Board of Directors approved a short-term shareholder rights agreement (“the Rights Agreement”) following an evaluation by the Shareholder Rights Committee established by the Board in August 2019. The Rights Agreement is intended to ensure that all PolarityTE shareholders receive fair treatment in any potential transaction, while allowing the Board and shareholders adequate time to make informed strategic decisions that the Board and the Company’s executive management team are currently evaluating. The Rights Agreement is not intended to deter offers that are fair and otherwise in the best interests of PolarityTE’s shareholders.

  • Business Wire

    PolarityTE to Report Calendar Third Quarter Financial Results on November 12, 2019

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report calendar third quarter 2019 financial results by press release on Tuesday, November 12, 2019 at approximately 4:00 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Tuesday, November 12, 2019 at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-866-548-4713 (U.S. and Canada) or +44 (0)330 336 9105 (International) with confirmation code 6761138 and referencing “PolarityTE Third Quarter 2019 Earnings Call.” A webcast of the conference call can be accessed by using the link below.

  • Business Wire

    PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient's own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments. The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019.

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of National General Holdings, Natural Health Trends, Omnicell, and Polarity TE and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of National General Holdings Corp. (NGHC), Natural Health Trends Corp. (NHTC), Omnicell, Inc. (OMCL), and PolarityTE, Inc. (PTE) on behalf of long-term stockholders.  More information about each potential case can be found at the link provided. Bragar Eagel and Squire is investigating certain officers and directors of National General Holdings Corp. following a class action complaint that was filed against National General on July 25, 2019.

  • Business Wire

    SkinTE Data to be Presented at the 19th Annual Diabetic Foot Global Conference

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that two abstracts demonstrating the impact of the Company’s SkinTE™ product in treating diabetes-related wounds were accepted for poster presentations at the 2019 Diabetic Foot Global Conference (DFCon), an international, interdisciplinary diabetic foot conference hosted by the Keck School of Medicine of University of Southern California in collaboration with Baylor College of Medicine and University of California San Francisco from October 17-19, 2019 in Los Angeles. Today’s announcement further signifies the Company’s momentum with its clinical research program, bringing the total SkinTE data presentations at medical conference in 2019 to 36, of which 14 were podium presentations.

  • SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting
    PR Newswire

    SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting

    Podium Presentation to Highlight a Variety of SkinTE Clinical Results in Trauma, Wound, and Burn from a 15 Patient Case Series SALT LAKE CITY , Sept. 9, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: ...

  • PolarityTE Appoints Peter Cohen as Chairman of the Board
    PR Newswire

    PolarityTE Appoints Peter Cohen as Chairman of the Board

    SALT LAKE CITY, Sept. 4, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Peter Cohen, previously Lead Director, as Chairman of the Board. "It gives me great satisfaction to lead the Board during this important time at PolarityTE.  I am proud to be part of a company with such an innovative technology, which not only addresses an unmet medical need, but has the potential to become a mainstay treatment in the field of skin and tissue regeneration," said Mr. Cohen.  "There have been growing pains and unexpected challenges in the development of PolarityTE, which can occur with innovative companies, especially those that have the potential to disrupt the biotechnology industry.  I am pleased with the strides we have made to address these growing pains and challenges, and believe we have the right, disciplined approach to best position the business for growth.

  • PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference
    PR Newswire

    PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference

    SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 in New York, NY. PolarityTE also announced that it will attend and meet with investors during the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York, NY. PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • PolarityTE Granted Canadian Patent
    PR Newswire

    PolarityTE Granted Canadian Patent

    SALT LAKE CITY , Aug. 20, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that ...

  • PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
    PR Newswire

    PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds

    SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone.

  • PolarityTE Reports Second Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports Second Calendar Quarter 2019 Results

    SALT LAKE CITY , Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019
    PR Newswire

    PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019

    SALT LAKE CITY, July 25, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar second quarter 2019 financial results by press release on Thursday, August 8, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Thursday, August 8, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-394-8218 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 1393700 and referencing "PolarityTE Second Quarter 2019 Earnings Call".  A webcast of the conference call can be accessed by using the link below.

  • PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
    PR Newswire

    PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE

    SALT LAKE CITY, June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs). The data was presented at the American Diabetes Association's 79th Scientific Sessions conference. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.

  • PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance
    PR Newswire

    PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance

    SALT LAKE CITY, June 3, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) today announced that the Board of Directors has created the Office of the Chief Executive, consisting of a team of three senior executives who will focus and collaborate on commercialization, operational and financial performance, and new product development. Members of the Office of the Chief Executive include Richard Hague, Chief Operating Officer, Paul Mann, Chief Financial Officer and David Seaburg, President of Corporate Development.  Dr. Denver Lough remains the Chairman of the Board and is on indefinite administrative leave from the offices of Chief Executive Officer and Chief Research & Development Officer.

  • Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference
    PR Newswire

    Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference

    SALT LAKE CITY, May 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that final data from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs), will be presented at the American Diabetes Association's 79th Scientific Sessions conference at the Moscone Center in San Francisco, California. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. The poster, Results of a Pilot Evaluation of a Novel Autologous Homologous Skin Construct Treatment of Diabetic Foot Wounds Refractory to Conventional Treatments (#45-LB), will be presented on Sunday, June 9, 2019 from 12:00 PM – 1:00 PM by David G. Armstrong, MD, PhD, DPM, Professor of Clinical Surgery at the Keck School of Medicine at the University of Southern California and co-Director of the Southwestern Academic Limb Salvage Alliance.

  • PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE
    PR Newswire

    PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE

    SALT LAKE CITY, May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today data from two pilot studies on the use of its SkinTE™ product both showing successful closure of diabetic foot ulcers (DFUs) and venous stasis leg ulcers (VLUs) within a 12-week period. The cases involved patients with lower extremity chronic wounds that were difficult to treat or had failed to heal with standard dressing care and conventional treatments, using a single application of SkinTE. The data from each of the clinical case series was presented yesterday at the Symposium on Advanced Wound Care (SAWC) spring conference in San Antonio, TX.

  • PolarityTE Reports First Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports First Calendar Quarter 2019 Results

    SALT LAKE CITY , May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...